

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM557779

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT OF THE ENTIRE INTEREST AND THE GOODWILL		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
Maelor Laboratories Limited		01/15/2020	limited company: ENGLAND
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	Alliance Pharmaceuticals Limited		
<b>Street Address:</b>	Avonbridge House		
<b>Internal Address:</b>	Bath Road		
<b>City:</b>	Chippenham, Wiltshire		
<b>State/Country:</b>	UNITED KINGDOM		
<b>Postal Code:</b>	SN15 2BB		
<b>Entity Type:</b>	limited company: ENGLAND		
<b>PROPERTY NUMBERS Total: 2</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Registration Number:</b>	2961066	RINCINOL	
<b>Registration Number:</b>	3750797	CANKER-X	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	3146673633		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	314-552-6000		
<b>Email:</b>	ipdocket@thompsoncoburn.com		
<b>Correspondent Name:</b>	Shoko Naruo		
<b>Address Line 1:</b>	Thompson Coburn LLP		
<b>Address Line 2:</b>	One US Bank Plaza		
<b>Address Line 4:</b>	St. Louis, MISSOURI 63101		
<b>ATTORNEY DOCKET NUMBER:</b>	66886-190068		
<b>NAME OF SUBMITTER:</b>	Shoko Naruo		
<b>SIGNATURE:</b>	/Shoko Naruo/		
<b>DATE SIGNED:</b>	01/16/2020		
<b>Total Attachments: 4</b>			
source=Signed Confirmatory Assignment#page1.tif			
source=Signed Confirmatory Assignment#page2.tif			

CH \$65.00 2961066

source=Signed Confirmatory Assignment#page3.tif

source=Signed Confirmatory Assignment#page4.tif

## TRADEMARK ASSIGNMENT

WHEREAS, Maelor Laboratories Limited, a limited company incorporated in England having its registered office at Avonbridge House, Bath Road, Chippenham, Wiltshire, SN15 2BB, United Kingdom ("Assignor"), owns the entire right, title and interest in and to the trademarks identified in Exhibit A (hereinafter referred to collectively as the "Trademarks"); and

WHEREAS, Alliance Pharmaceuticals Limited, a limited company incorporated in England its registered office at Avonbridge House, Bath Road, Chippenham, Wiltshire, SN15 2BB, United Kingdom, is desirous of securing all of Assignor's right, title and interest in and to the Trademarks, and the goodwill of Assignor's business associated therewith.

NOW THEREFORE, in consideration of the covenants and obligations set forth in that certain Intellectual Property Assignment, dated as of August 7, 2018, by and among Maelor Laboratories Limited and Alliance Pharmaceuticals Limited (the "Intellectual Property Assignment"), and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

1. Assignor hereby assigns to Assignee the entire right, title and interest in and to the Trademarks, together with the goodwill of Assignor's business associated therewith, and the right to sue for, and recover for, any past and future infringements thereof, to be held and enjoyed by Assignee, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by Assignor had no assignment of said Trademarks been made.

2. Assignor shall, upon the request of Assignee, execute any further documents reasonably required by Assignee to secure and enforce the rights granted to Assignee under this Trademark Assignment.

3. This Trademark Assignment is executed pursuant to and subject to the terms and conditions of the Intellectual Property Assignment.

[Signature page follows.]

IN WITNESS WHEREOF, I have hereunto set my hand the 15 day of January, 2020.

Maelor Laboratories Limited

By:   
Name: Andrew Franklin  
Title: Chief Financial Officer

IN WITNESS WHEREOF, I have hereunto set my hand the 15 day of January, 2020.

Alliance Pharmaceuticals Limited

By:   
Name: Peter Butterfield  
Title: Chief Executive Officer

Exhibit A

Mark	Registration Date	Owner Information
<u>SEBCLAIR</u> RN: 4386844	Registered August 20, 2013	Maelor Laboratories Limited (England Company)
<u>RINCINOL</u> RN: 2961066	Registered: June 7, 2005	Maelor Laboratories Limited (England Company)
<u>CANKER-X</u> RN: 3750797	Registered: February 16, 2010	Maelor Laboratories Limited (England Company)

